Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of LIV-GAMMA SN Inj.10% for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• LIV-GAMMA SN Inj.10%

Snippet

Sponsor: SK Plasma Co., Ltd. | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED